Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Akeso Starts Phase III Trial of PD-1/VEGF Bispecific for NSCLC

publication date: Aug 18, 2023

Guangzhou Akeso has dosed the first patient in a China Phase III trial of ivonescimab, an investigational PD-1/VEGF bi-specific antibody. It will be tested as a first-line treatment in patients with locally advanced or metastatic squamous non-small cell lung cancer. In late 2022, Akeso out-licensed global ex-China rights for ivonescrimab in a $5 billion agreement with Summit Therapeutics of Menlo Park, CA. The Phase III trial will evaluate the clinical efficacy and assess the safety of ivonescimab compared with BeiGene’s PD-1 candidate, tislelizumab, in combination with chemotherapy. More details....

Stock Symbols: (HK: 9926) (NSDQ: SMMT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital